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M A J O R A R T I C L E
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Background. Intensive treatment of hematological malignancies with hematopoietic stem cell transplantation
(HSCT) is accompanied by a high incidence of opportunistic invasive fungal infection, but individual risk varies
significantly. Dectin-1, a C-type lectin that recognizes 1,3-b-glucans from fungal pathogens, including Candida
species, is involved in the initiation of the immune response against fungi.
Methods. Screening for the DECTIN-1 Y238X polymorphism within a group of 142 patients undergoing HSCT
was correlated with Candida colonization and candidemia. Furthermore, functional studies were performed on
the consequences of the polymorphism.
Results. Patients bearing the Y238X polymorphism in the DECTIN-1 gene were more likely to be colonized
with Candida species, compared with patients bearing wild-type DECTIN-1, necessitating more frequent use of
fluconazole in the prevention of systemic Candida infection. Functional assays demonstrated a loss-of-function
phenotype of the polymorphism, as shown by the decreased cytokine production by immune cells bearing this
polymorphism.
Conclusions. The Y238X polymorphism is associated with increased oral and gastrointestinal colonization with
Candida species. This suggests a crucial role played by dectin-1 in the mucosal antifungal mechanisms in im-
munocompromised hosts. The finding that DECTIN-1 polymorphisms rendered HSCT recipients at increased risk
for fungal complications may contribute to the selection of high-risk patients who should be considered for
antifungal prophylaxis to prevent systemic candidiasis.
The treatment of patients with hematological malig-
nancies with a hematopoietic stem cell transplantation
(HSCT) following myeloablative conditioning is ac-
companied by complications that include mucosal bar-
rier injury, prolonged neutropenia, and graft-versus-
host disease (GvHD), all of which contribute to fungal
and other opportunistic infections [1, 2]. Traditional
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risk factors are predictive for incidence of invasive fun-
gal disease in general, but the individual risk is more
difficult to determine, although this is needed for a
more guided use of antifungal prophylaxis and therapy.
Dectin-1 is a member of the C-type lectin receptor
family that recognizes the b-1,3-glucan motif of the cell
wall of pathogenic fungi [3]. Dectin-1 is mainly ex-
pressed by immune cells of the myeloid lineage (neu-
trophils, macrophages, and dendritic cells). Several
studies have shown that dectin-1 belongs to the ar-
mamentarium of immune cells against fungal patho-
gens, including Candida species and Aspergillus species
[4, 5]. Furthermore, dectin-1 synergizes with TLR2 and
TLR4 signals and promotes Th1 and Th17 responses
to activate antifungal host defense [6–8].
Recently, we have demonstrated that a polymor-
phism in DECTIN-1 (Y238X, rs 16910526) is respon-
 at K
atholieke U
niversiteit on July 10, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Dectin-1 in Fungal Colonization and HSCT • CID 2009:49 (1 September) • 725
sible for recurrent mucocutaneous fungal infections in a Dutch
family (unpublished data). This polymorphism resulted in an
early stop codon, which leads to the loss of the last 10 amino
acids of the extracellular domain, and in a diminished capacity
to bind b-glucans.
To test the hypothesis that DECTIN-1 variants influence the
susceptibility to fungal infection in general and to Candida
infection in particular for HSCT recipients, we first assessed
the frequency of DECTIN-1 polymorphisms in a healthy Dutch
population. We identified the Y238X mutation as an important
polymorphism and the only one with significant functional
consequences for the recognition of Candida species. Subse-
quently, we have investigated the impact of this DECTIN-1
polymorphism on the incidence of mucosal Candida coloni-
zation and the occurrence of candidemia and other invasive
fungal infections among 142 patients who received a sibling T
cell–depleted allogeneic HSCT.
PATIENTS, MATERIALS, AND METHODS
Genetic screening for DECTIN-1 polymorphisms. DNA tem-
plate of the DECTIN-1 gene (also named CLEC7A) was taken
from GenBank, chromosome position 12p13, NC_000012.10.
Sequencing of the exonic and nearby intronic regions of the
DECTIN-1 gene in the 138 healthy volunteers was per-
formed by applying the primers and conditions depicted in
table 1. Genotyping for the presence of the Y238X polymor-
phism in the patient and donor groups was performed by ap-
plying the TaqMan single-nucleotide polymorphism (SNP) as-
say C_33748481_10 on the 7300 ABI Real-Time polymerase
chain reaction system (Applied Biosystems). Patients, donors,
and healthy volunteers had given informed consent to pro-
spective collection of DNA samples for investigational use.
Flow cytometry. For staining of membrane-bound dectin-
1, monocytes were incubated with 5 mg/mL murine anti–dectin-
1 directed towards the stalk region (BD6) conjugated with bi-
otin, or mouse immunoglobulin (Ig) G2b isotype control,
followed by streptavidin–allophycocyanin conjugated goat anti-
mouse antibody (Pharmingen). Dectin-1 expression was de-
termined by flow cytometry (FACScalibur; BD Biosciences).
Confocal microscopy. Confocal laser scanning microscopy
was performed as described by Meyer-Wentrup et al [9]. Cells
were stained with 10 mg/mL mouse anti–dectin-1 (clone
259931; R&D Systems) or mouse IgG2b isotype control, fol-
lowed by goat anti-mouse-Alexa647–conjugated secondary an-
tibody (Molecular Probes). Samples were mounted in mowiol
and analyzed by confocal laser scanning microscopy (Olympus
FV1000).
Cytokine stimulation assays. Isolation of mononuclear
cells was performed as described previously [6]. Cells were
incubated at 37C for the indicated duration (4 h or 48 h) with
either culture medium or the various stimuli: 105 heat-killed
Candida albicans (heat-killed by incubation at 56C for 30 min),
the TLR2 agonist Pam3Cys (10 mg/mL) and b-glucan (10 mg/
mL) or a combination of Pam3Cys and b-glucan. In a part of
the experiments, after peripheral blood mononuclear cell
(PBMC) isolation, monocytes were purified by CD14+ MACS
MicroBeads (Miltenyi Biotec) and stimulated as described
above. Cytokine production was measured by enzyme-linked
immunosorbent assay (R&D Systems).
Patients and donors. We performed a retrospective analysis
involving 142 Dutch patients undergoing HSCT because of
hematological malignancies. The patients and donors were con-
secutively admitted to our transplant unit from May 1996
through September 2007 for a human leukocyte antigen–iden-
tical sibling, partially T cell–depleted allogeneic HSCT. The
characteristics of patients, donors, and HSCT procedures are
given in table 2.
Treatment protocol. The treatment protocol has been de-
scribed in detail elsewhere [10]. The conditioning regimen con-
sisted of cyclophosphamide (60 mg/kg for 2 days) in combi-
nation with either total body irradiation (4.5 Gy for 2 days)
or busulfan (4 mg/kg for 4 days). Idarubicin (42 mg/kg in 48
h) was often added to these conditioning regimen to reduce
the risk of relapse in the setting of T cell–depleted HSCT [11].
On day 0, all patients were given an allogeneic HSCT containing
CD34+ cells/kg (range, 0.6–11.6 CD34+ cells/kg) and63.2 10
CD3+ cells/kg (range, 0.1–0.8 CD3+ cells/kg).60.5 10
Antimicrobial prophylaxis consisted of 500 mg of ciproflox-
acin given twice daily and 500 mg of valaciclovir given 3 times
daily. Surveillance cultures for Candida were collected twice
weekly from hospital admission until hospital discharge, with
the first culture samples obtained on the day of hospital ad-
mission, before the start of conditioning. Fluconazole (200 mg
daily) was only prescribed to those who were colonized with
C. albicans, Candida tropicalis, or Candida parapsilosis (not
Candida krusei or Candida glabrata) when the yeast was present
in both fecal cultures and mouth washes obtained on the same
day, or when obtained from the same site on 2 consecutive
occasions [12].
Invasive fungal infections were defined according to the Eu-
ropean Organization for the Treatment of Cancer/Mycoses
Study Group consensus guidelines, designating invasive fungal
disease as possible, probable, or proven [13]. Oral mucositis
was graded daily according to the validated Nijmegen Nursing
Mucositis Scoring System (NNMSS) [14]. Acute GvHD was
diagnosed by clinical signs or pathological examination of skin,
gut, or liver biopsy samples and was graded according to the
criteria of Glucksberg et al [15].
Statistical analysis. In multivariable logistic regression
analyses, we investigated the association of the DECTIN-1 status
of the patient with Candida colonization, controlling for un-
derlying hematological disease, age, and sex of the patient. In
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Table 1. Primers and Polymerase Chain Reaction Conditions Applied to
Amplify Every Exon and Proximal Intronic Regions of the DECTIN-1 Gene
to Perform Sequence Analysis
Exon, primer Sequence, 5’–3’ MgCl2, mM
Annealing
temperature
1
Forward TTTCACCACGTTAGCCAAGCT 2.5 52C
Reverse CTGAAATAGTTTGCATCGGTT
2
Forward CCCTTTATAAGTGAAATGGGC 1.75 60C
Reverse ACCGTGCAAGGCCAGATTTT
3
Forward 1 GCCAGTGATAAATCAGTTACT 3.5 56C
Reverse 1 TTCTTCTTCTCCACCTTCTT
Forward 2 TGGCAACATTTTCCCTTCTT 3.5 56C
Reverse 2 GGCAAGGGCATAGTTAAAGG
4
Forward TCATTACCTGGAATCTCCCTCT 2.5 56C
Reverse TGGCAACTAATTGGTTATTTCA
5
Forward GCTGCTCGACAGAGGTTTTC 1.75 62C
Reverse GGATGGTCTCGATCTCCTGA
6
Forward AATCACAGCCTCTCCCTTCA 2.5 60C
Reverse GATTTAAGCCTCCTTTTCCAA
NOTE. For all amplicons, sequence analyses were carried out with the forward and
the reverse primer. For the sequences of exon 3, technical difficulties were encountered.
Therefore, we amplified exon 3 with 2 different primer pairs and aligned both forward
assays after sequence analysis.
the analysis on the impact of early candidemia, the DECTIN-
1 status of only patients, but not of the donors, was considered
of importance. Early candidemia was defined as that occurring
on day 21 or earlier. In myeloablative stem cell transplantation,
monocyte recovery usually occurs only 3–4 weeks after HSCT
[16], and therefore, the genetic make-up of the donor is not
considered to be relevant for the susceptibility to early candi-
demia. The association between the DECTIN-1 status of the
patient and the occurrence of early candidemia was studied
using logistic regression models that accounted for confounding
by including the age of patient, the underlying disease, the
duration of neutropenia, the presence of colonization at hos-
pital admission, and the presence of GvHD. In contrast, in the
analysis of the impact of proven and probable invasive mold
infections up to day 100, the DECTIN-1 status of both patients
and donors was included.
To compare percentages between 2 independent groups, we
used the x2 test or Fisher’s exact test when appropriate. Dif-
ferences in the cytokine production capacity were tested by the
Student’s t test. was considered to represent a statisticallyP ! .05
significant difference.
RESULTS
DECTIN-1 polymorphism screening in healthy individuals.
Genetic variation in the DECTIN-1 gene was investigated for
138 Dutch healthy volunteers and revealed the polymorphisms
shown in figure 1. A small number of polymorphisms were
identified, with the Y238X (rs16910526) in exon 6 being the
only exonic polymorphism. This polymorphism was present in
19 (13.8%) of 138 individuals, all of whom were heterozygous,
resulting in an allele frequency of 6.9%. This polymorphism
was identified earlier in a family that had previously been an-
alyzed for mucocutaneous Candida infection (unpublished
data); 3 members of this family were homozygous for the
Y238X polymorphism.
Dectin-1 protein expression. We investigated the conse-
quence of the polymorphism on dectin-1 expression and lo-
calization at the protein level. Monocytes isolated from indi-
viduals who were homozygous for the wild-type DECTIN-1
allele and from individuals heterozygous or homozygous for
the Y238X polymorphism were analyzed for dectin-1 expres-
sion by flow cytometry and confocal microscopy. Monocytes
from the individuals homozygous for the Y238X polymorphism
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Table 2. Clinical Characteristics of the Study Group
Variable
Homozygous
wild-type for
DECTIN-1
Heterozygous for
DECTIN-1 Y238X P
No. of recipients 126 15
No. of donors 116 22
Male sex, %
Recipients 65 60 .78
Donors 56 64 .64
Age, mean years (range)
Recipients 47.5 (18.5–64.4) 42.8 (19.2–59.8) .11
Donors 47.4 (14–75.6) 43.3 (23.8–67.6) .24
Diagnosis .79
AML/ALL 60 (47.6) 8 (53.3)
CML/MPS 26 (20.6) 3 (20)
MDS 23 (18.3) …
Lymphoma/CLL 17 (13.5) 4 (26.7)
Conditioning regimen .25
Ida-Cyclo-TBI 79 (62.7) 10 (66.7)
Ida-Cyclo-Bus 15 (11.9) 1 (6.7)
Cyclo-TBI 27 (21.4) 1 (6.7)
Cyclo-Bus 5 (4.0) 3 (20)
TBI 106 (84.1) 11 (73.3)
Stem cell source 1.99
Peripheral blood 72 (57.1) 9 (60.0)
Bone marrow 54 (42.9) 6 (40.0)
T cell depletion .43
CD34 selection 61 (48.5) 9 (60.0)
Counterflow elutriation 41 (32.5) 4 (26.7)
CD3/CD19 selection 24 (19.0) 2 (13.3)
Duration of neutropenia,a mean days (range) 11.9 (6–20) 11.0 (6–15) .23
Acute GvHD .77
Grade 0–I 81 (64.3) 11 (73.3)
Grade II-IV 39 (31.0) 4 (26.7)
Grade III-IV 10 (7.9) 1 (6.7)
NA 6 (4.7) …
NOTE. Data are no. (%) of patients, unless otherwise indicated. All patients received a human leukocyte
antigen–matched sibling partially T cell–depleted hematopoietic stem cell transplant. Graft-versus-host dis-
ease (GvHD) prophylaxis consisted of only cyclosporine for all patients. Differences between the study
groups were compared using the Pearson x2 test or Fisher’s exact test and with the use of the independent
Student’s t test where appropriate. No statistically significant differences were obtained. AML/ALL, acute
myeloid and lymphatic leukemia; Bus, busulphan; CLL, chronic lymphatic leukemia; CML/MPS, chronic
myeloid leukemia/myeloproliferative syndrome; Cyclo, cyclophosphamide; Ida, idarubicin; MDS, myelod-
ysplastic syndrome; NA, not applicable; TBI, total body irradiation.
a Neutropenia was defined as cells/L.9 0.110
exhibited no dectin-1 expression on the cell surface, whereas
cells from individuals heterozygous for the Y238X polymor-
phism had intermediate cell surface expression, compared with
cells from individuals with the wild-type allele (figure 2A). In
line with this, no cell surface expression of dectin-1 could be
detected on monocytes isolated from individuals who were ho-
mozygous for the Y238X polymorphism, in contrast with wild-
type cells, when monocytes were analyzed by confocal micros-
copy (figure 2B). However, dectin-1 mRNA expression was
demonstrated to be equal between the genotypes (data not
shown). Thus, these findings demonstrate that dectin-1 pro-
tein expression is absent from the cell membrane of mono-
cytes from individuals who are homozygous and interme-
diate on monocytes from individuals who are heterozygous
for the Y238X polymorphism.
Cytokine production. Functional consequences of the
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Figure 1. Schematic drawing of the DECTIN-1 gene (also known as CLEC7A), consisting of an N-terminal cytoplasmatic tail (Cyto), encoded by exon
1, a transmembrane region (TM; exon 2), a stalk region (exon 3), and the carbohydrate recognition domain (CRD; exon 4–6). Intronic polymorphisms
were detected in 5’UTR, intron 2, intron 3, exon 6, and 3’UTR. All variations are depicted together with their corresponding chromosome location and
rs number, if available.
Y238X polymorphism were investigated in monocytes and
PBMCs isolated from individuals bearing only the wild-type
DECTIN-1 allele and individuals who were heterozygous or
homozygous for the Y238X polymorphism. Interleukin (IL)–
1b induction by C. albicans was lower in cells from individuals
bearing the Y238X polymorphism (figure 3A; ). Dectin-P ! .05
1 has been previously demonstrated to amplify TLR2 signaling
[6]; this effect was absent in cells isolated from individuals
homozygous for the Y238X allele (figure 3B). In contrast, IL-
18 and interferon (IFN)–g production was not defective in cells
isolated from these individuals (figure 3C; significant).Pp not
Although a tendency toward a lower IL-18 production capacity
has been observed in cells from individuals heterozygous for
Y238X, compared with cells bearing only the wild-type DEC-
TIN-1 allele, this did not reach statistical significance. IL-18
production in cells from individuals homozygous for the Y238X
mutation was similar to production in cells from individuals
with the wild-type allele. Furthermore, IFN-g production ca-
pacity is practically equal between the genotypes.
DECTIN-1 Y238X polymorphism in patients and donors.
The DECTIN-1 genetic status could be determined for 141
patients and 138 donors. Insufficient amounts of DNA pre-
cluded the determination of genetic status in 1 patient and 4
donors. Fifteen (10.6%) of 141 patients and 22 (15.9%) of 138
donors had the DECTIN-1 Y238X polymorphism; all individ-
uals were heterozygous. In 9 patient-donor pairs, both indi-
viduals were heterozygous for the polymorphism. There were
no statistically significant differences between the clinical char-
acteristics of patients with and patients without the DECTIN-
1 Y238X polymorphism (table 2). No difference was detected
in the severity of mucositis between patients with and patients
without the DECTIN-1 Y238X polymorphism, with a mean
NNMSS score of 3.8 vs 3.9 on day 0 and 7.2 vs 7.6 on day 7
( significant.).Pp not
Candida species colonization. Seven patients who received
secondary antifungal prophylaxis at hospital admission were
excluded from the study, as were 11 patients with missing col-
onization data, leaving 124 patients eligible for analysis of Can-
dida colonization. At hospital admission, 46 (37.1%) of 124
patients were colonized with Candida species. Patients who
were heterozygous for the Y238X polymorphism were statis-
tically significantly more often colonized than were patients
with DECTIN-1 wild-type alleles (11 [84.6%] of 13 vs 35
[31.5%] of 111; ) (odds ratio [OR], 11.9; 95% confi-P ! .001
dence interval [CI], 2.5–56.8). After adjusting for diagnosis, the
OR was 12.2 (95% CI, 2.5–59.7); after adjusting for patient age
and sex, the OR was 12.0 (95% CI, 2.5–57.1). On the day of
HSCT (day 0), this difference persisted: 12 (92.3%) of 13 pa-
tients vs 50 (45.1%) of 111 patients ( ). The unadjustedPp .001
OR was 14.6 (95% CI, 1.8–116.5) and the OR adjusted for
diagnosis, patient age, and sex was 15.5 (95% CI, 1.9–125.6).
Patients with a DECTIN-1 polymorphism were more likely
than other patients to receive fluconazole (9 [69.2%] of 13 vs
42 [37.8%] of 111; ) (table 3). Among those patientsPp .03
who received fluconazole, eradication was achieved in 1
(11.1%) of 9 patients who were heterozygous for the Y238X
polymorphism, compared with 14 (33.3%) of 42 patients who
bore only the wild-type DECTIN-1 allele ( ). ColonizingPp .25
species were C. albicans (87% of patients), C. glabrata (8.1%),
and sporadically, C. krusei, Candida kefyr, Candida parapsilosis,
and Candida dubliniesis (1.6% each). No difference in the fre-
quency of colonization with particular Candida species was
observed between patients who were heterozygous for Y238X
and patients who bore only the wild-type DECTIN-1 allele.
Invasive fungal disease. Patients who received early anti-
fungal prophylaxis with either itraconazole, voriconazole, or
posaconazole, starting from day 0 or earlier and until day 21,
were excluded (18 patients, 7 of whom had received secondary
prophylaxis and 11 of whom had participated in antimicrobial
studies). The overall incidence of candidemia until day 21 was
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Figure 2. Flow cytometry graphs of extracellular dectin-1 staining (A) and (B) fluorescent confocal staining of dectin-1 (right panel) and light
microscopic image (left panel) on unstimulated monocytes derived from individuals homozygous for the wild-type DECTIN-1 allele (WT) and heterozygous
(HET) or homozygous (HOM) for the DECTIN-1 Y238X polymorphism.
8.9% (11 of 123 patients). There was no statistically significant
difference in the incidence of early candidemia between patients
with and patients without the DECTIN-1 Y238X polymorphism
(2 [18.2%] of 11 vs 9 [8.0%] of 112; ) (table 3); thePp .26
OR was 2.5 (95% CI, 0.5–13.6). However, this study was not
designed to detect differences in the risk of developing invasive
candidiasis, because patients who were colonized were pre-
scribed fluconazole to prevent systemic Candida infection, and
the study was underpowered to find a difference.
Candidemia was caused by C. albicans in 7 of 11 cases, with
the remainder of the cases being due to C. glabrata (1 case),
C. parapsilosis (2), and C. dubliniesis (1). Eight (15.7%) of 51
patients who were colonized and received fluconazole experi-
enced candidemia. Two (3.6%) of 55 patients who were not
colonized and who therefore received no fluconazole developed
candidemia.
The incidence of proven and probable invasive mold infec-
tion up to day 100 was 3.3% (4 of 120 patients), with 4 probable
and no proven mold infections. Three probable cases were due
to Aspergillus species, and 1 probable case was due to Rhizo-
mucor species. There was no statistically significant difference
between pairs with and without a DECTIN-1 Y238X poly-
morphism; 1 (5.0%) of 20 patients with the Y238X polymor-
phism had a probable case, compared with 3 (3.0%) of 100
patients with the DECTIN-1 wild-type allele ( ) (tablePp .52
3). However, the study was underpowered to detect a difference,
especially because of the very low incidence of mold infection.
DISCUSSION
In this study, we demonstrate that a newly characterized poly-
morphism in DECTIN-1 is associated with increased suscep-
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Figure 3. Cytokine production capacity of interleukin (IL)–1b, IL-18, and interferon (IFN)–g after stimulation of monocytes during 4 h (A) or peripheral
blood mononuclear cells (PBMCs) during 48 h with b-glucan, Pam3Cys, or b-glucan/Pam3Cys (B) or with heat-killed Candida albicans (C). Cells were
obtained from individuals with the wild-type allele (WT; ) or individuals heterozygous (HET; ) or homozygous (HOM; ) for the DECTIN-np 5 np 4 np 3
1 Y238X polymorphism. Data are percentages compared with WT ( standard deviation). * .P ! .05
tibility to fungal colonization among HSCT recipients. As a
consequence, among patients who were immunocompromised
as a result of HSCT, the need to prescribe fluconazole to prevent
systemic Candida infection was, in part, defined by the presence
of this polymorphism.
Dectin-1 is one of the most important pattern recognition
receptors for fungal pathogens in general and Candida species,
in particular. Polymorphisms in pattern recognition receptors
are known to be associated with an increased susceptibility to
fungal infection [17, 18]. We hypothesized that genetic variants
of DECTIN-1 could influence susceptibility to Candida colo-
nization and infection in HSCT recipients.
Screening of all 6 exons of the DECTIN-1 gene in a healthy
Dutch population revealed 1 exonic polymorphism and several
intronic SNPs. Because the intronic SNPs are not likely to affect
dectin-1 function, we considered the Y238X polymorphism to
be the only polymorphism that could alter dectin-1 function
and could influence susceptibility to fungal infection.
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Table 3. Observed Candida Species Colonization and Invasive Fungal Disease among Hematopoietic
Stem Cell Transplant Recipients
Clinical outcome
Percentage (ratio) of recipients
P OR
Homozygous
wild-type for
DECTIN-1
Heterozygous for
DECTIN-1 Y238X
Candida species colonization at hospital admission 31.5 (35/111) 84.6 (11/13) !.001 11.9
Candida species colonization on day of HSCT (day 0) 45.1 (50/111) 92.3 (12/13) .001 14.6
Surveillance-culture guided fluconazole therapy 37.8 (42/111) 69.2 (9/13) .03 3.7
Early candidemia (day 21 or earlier) 8.0 (9/112) 18.2 (2/11) .26 2.5
Invasive mold disease (day 100 or earlier) 3.0 (3/100) 5.0 (1/20) .52 1.7
NOTE. The genetic DECTIN-1 status of the patient-donor couples (either patient, donor, or both heterozygous for the
Y238X polymorphism) was included in this analysis of the impact of the polymorphism on the occurrence of invasive mold
disease on day 100 or earlier. HSCT, hematopoietic stem cell transplantation; OR, odds ratio.
To characterize the functional consequences of the Y238X
polymorphism in more detail, flow cytometry and confocal
microscopy were performed. Expression of dectin-1 was absent
on the cell membrane of cells isolated from individuals who
were homozygous for the Y238X allele, which suggested a de-
fective transport of the mutated form of dectin-1 to the cell
membrane. Accordingly, dectin-1 expression was intermedi-
ate on cells from individuals who were heterozygous for the
polymorphism.
After stimulation with heat-killed C. albicans or b-glucan,
IL-1b secretion was intermediate in cells isolated from indi-
viduals who were heterozygous for the Y238X polymorphism
and low in cells from individuals who were homozygous for
this polymorphism, compared with secretion in cells from in-
dividuals who were homozygous for the wild-type allele. More-
over, the previously described synergism between TLR2 and
dectin-1 signals [6] was completely absent in individuals ho-
mozygous for the Y238X polymorphism. These data demon-
strate the loss-of-function effect of the Y238X polymorphism
for dectin-1 activity. However, no difference in the production
of IL-18 and IFN-g could be observed between the different
DECTIN-1 genotypes. This could well be because of a certain
redundancy of dectin-1 signaling in production of these cy-
tokines, and this is accompanied by a normal Candida-killing
activity by neutrophils from individuals bearing the Y238X
polymorphism (data not shown), resulting in an adequate host
defense in systemic infections.
In the follow-up of these genetic and immunological studies,
we demonstrate that this polymorphism has a significant impact
on oral and gastrointestinal mucosal colonization with Candida
species in HSCT recipients, which defined the need for the use
of fluconazole in our approach. This is in line with the finding
of recurrent mucocutaneous candidiasis in a family with in-
dividuals who were homozygous for the DECTIN-1 polymor-
phism (unpublished data). The overall rate of fungal coloni-
zation at hospital admission was comparable to that in earlier
studies, with colonization rates of 28%–57% [19, 20]. These
data strongly support a role of dectin-1 mediated mechanisms
for mucosal anti-Candida defense.
The mechanisms of the increased susceptibility to mucosal
colonization with Candida in individuals bearing the DECTIN-
1 polymorphism cannot be definitively pinpointed, although
the defective cytokine responses are probably involved. Al-
though monocytes are important for mucosal defenses, epi-
thelial cells may also contribute to these effects. Interestingly,
the expression of dectin-1 on epithelial cells has been recently
demonstrated, and the interaction of these cells with fungal
pathogens leads to chemokine release [21]. One has to consider,
however, that in the setting of HSCT, both monocytes and
epithelial cells of the mucosa are damaged for a prolonged
period, although they are largely intact at hospital admission
and during the first days of conditioning. On the other hand,
the residential macrophages of the mucosa are less affected, and
it is most likely that the impact of the DECTIN-1 polymorphism
is exerted at their level.
The presence of the DECTIN-1 polymorphism did not result
in a significantly higher incidence of candidemia, although that
might have been expected, because mucosal colonization is
associated with systemic candidiasis in HSCT recipients who
experience mucosal barrier injury [22, 23]. Importantly, in this
cohort, patients were prescribed oral fluconazole when colo-
nized, which is known to reduce the incidence of candidemia
[20, 24]. Therefore, fluconazole was most likely a confounding
factor, precluding a definitive conclusion regarding the role of
the DECTIN-1 Y238X polymorphism for susceptibility to early
candidemia, although our data may suggest an increased risk
(OR, 2.5; 95% CI, 0.5–13.6). In addition, our study was un-
derpowered to study the impact of the polymorphism on the
occurrence of invasive mold infections because of the low in-
cidence of these infections.
In our culture-guided approach, fluconazole could safely be
withheld for those individuals who were not colonized with
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Candida species, preventing overtreatment and accompanied
adverse effects and costs. However, those individuals who were
colonized remained at significant risk for candidemia, neces-
sitating better ways to predict, determine, and treat colonization
at an early stage. Determining the DECTIN-1 status before
HSCT might be a factor contributing to a more risk-adapted
prophylactic approach. Because Candida colonization is asso-
ciated with invasive disease among HSCT recipients, we pro-
pose that patients bearing the polymorphism should be con-
sidered for antifungal prophylaxis to prevent systemic
candidiasis. Nevertheless, future studies in prospective trials are
necessary to further confirm the impact of this newly char-
acterized DECTIN-1 polymorphism and to define its role in
selecting adequate prophylaxis or early treatment for HSCT
recipients.
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